

# Global Antihyperuricemic Agents Market Growth 2023-2029

<https://marketpublishers.com/r/G88EC8BD1605EN.html>

Date: February 2023

Pages: 126

Price: US\$ 3,660.00 (Single User License)

ID: G88EC8BD1605EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Antihyperuricemic agents are also called anti-gout drugs. These drugs correct the overproduction or underexcretion of uric acid.

LPI (LP Information)' newest research report, the “Antihyperuricemic Agents Industry Forecast” looks at past sales and reviews total world Antihyperuricemic Agents sales in 2022, providing a comprehensive analysis by region and market sector of projected Antihyperuricemic Agents sales for 2023 through 2029. With Antihyperuricemic Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Antihyperuricemic Agents industry.

This Insight Report provides a comprehensive analysis of the global Antihyperuricemic Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antihyperuricemic Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antihyperuricemic Agents market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antihyperuricemic Agents and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antihyperuricemic Agents.

The global Antihyperuricemic Agents market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Antihyperuricemic Agents is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Antihyperuricemic Agents is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Antihyperuricemic Agents is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Antihyperuricemic Agents players cover Takeda Pharmaceuticals, Hikma, Wockhardt, West Ward Pharmaceuticals, Rhea Pharmaceutical, Medinova, Odan Laboratories, TEIJIN and Casper Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Antihyperuricemic Agents market by product type, application, key manufacturers and key regions and countries.

#### Market Segmentation:

##### Segmentation by type

Inhibit Uric Acid Production Agents

Promote Uric Acid Excretion Agents

Others

##### Segmentation by application

Hospital Pharmacies

Retail Pharmacies

## Online Pharmacies

This report also splits the market by region:

### Americas

United States

Canada

Mexico

Brazil

### APAC

China

Japan

Korea

Southeast Asia

India

Australia

### Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Takeda Pharmaceuticals

Hikma

Wockhardt

West Ward Pharmaceuticals

Rhea Pharmaceutical

Medinova

Odan Laboratories

TEIJIN

Casper Pharma

Dr. Reddys Laboratories

Teva

Zydus Pharmaceuticals

Mylan

Sun Pharmaceutical

APOTEX

NorthStar Healthcare

Ipca Laboratories

Accord Healthcare

Gentec Pharmaceutical Group

Indoco Remedies

Lupin

Waterstone Pharmaceuticals

ALP Pharm

Jiangsu Hengrui Medicine

Jiangsu Wanbang Biopharmaceuticals

Hangzhou Zhuyangxin Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical

KPC Pharmaceuticals

Tonghua Limin

## Beijing Jialin Pharmaceutical

### Key Questions Addressed in this Report

What is the 10-year outlook for the global Antihyperuricemic Agents market?

What factors are driving Antihyperuricemic Agents market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Antihyperuricemic Agents market opportunities vary by end market size?

How does Antihyperuricemic Agents break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global Antihyperuricemic Agents Annual Sales 2018-2029

- 2.1.2 World Current & Future Analysis for Antihyperuricemic Agents by Geographic Region, 2018, 2022 & 2029

- 2.1.3 World Current & Future Analysis for Antihyperuricemic Agents by Country/Region, 2018, 2022 & 2029

#### 2.2 Antihyperuricemic Agents Segment by Type

- 2.2.1 Inhibit Uric Acid Production Agents

- 2.2.2 Promote Uric Acid Excretion Agents

- 2.2.3 Others

#### 2.3 Antihyperuricemic Agents Sales by Type

- 2.3.1 Global Antihyperuricemic Agents Sales Market Share by Type (2018-2023)

- 2.3.2 Global Antihyperuricemic Agents Revenue and Market Share by Type (2018-2023)

- 2.3.3 Global Antihyperuricemic Agents Sale Price by Type (2018-2023)

#### 2.4 Antihyperuricemic Agents Segment by Application

- 2.4.1 Hospital Pharmacies

- 2.4.2 Retail Pharmacies

- 2.4.3 Online Pharmacies

#### 2.5 Antihyperuricemic Agents Sales by Application

- 2.5.1 Global Antihyperuricemic Agents Sale Market Share by Application (2018-2023)

- 2.5.2 Global Antihyperuricemic Agents Revenue and Market Share by Application (2018-2023)

- 2.5.3 Global Antihyperuricemic Agents Sale Price by Application (2018-2023)

### **3 GLOBAL ANTIHYPERURICEMIC AGENTS BY COMPANY**

#### 3.1 Global Antihyperuricemic Agents Breakdown Data by Company

3.1.1 Global Antihyperuricemic Agents Annual Sales by Company (2018-2023)

3.1.2 Global Antihyperuricemic Agents Sales Market Share by Company (2018-2023)

#### 3.2 Global Antihyperuricemic Agents Annual Revenue by Company (2018-2023)

3.2.1 Global Antihyperuricemic Agents Revenue by Company (2018-2023)

3.2.2 Global Antihyperuricemic Agents Revenue Market Share by Company (2018-2023)

#### 3.3 Global Antihyperuricemic Agents Sale Price by Company

#### 3.4 Key Manufacturers Antihyperuricemic Agents Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Antihyperuricemic Agents Product Location Distribution

3.4.2 Players Antihyperuricemic Agents Products Offered

#### 3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

#### 3.6 New Products and Potential Entrants

#### 3.7 Mergers & Acquisitions, Expansion

### **4 WORLD HISTORIC REVIEW FOR ANTIHYPERURICEMIC AGENTS BY GEOGRAPHIC REGION**

#### 4.1 World Historic Antihyperuricemic Agents Market Size by Geographic Region (2018-2023)

4.1.1 Global Antihyperuricemic Agents Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Antihyperuricemic Agents Annual Revenue by Geographic Region (2018-2023)

#### 4.2 World Historic Antihyperuricemic Agents Market Size by Country/Region (2018-2023)

4.2.1 Global Antihyperuricemic Agents Annual Sales by Country/Region (2018-2023)

4.2.2 Global Antihyperuricemic Agents Annual Revenue by Country/Region (2018-2023)

#### 4.3 Americas Antihyperuricemic Agents Sales Growth

#### 4.4 APAC Antihyperuricemic Agents Sales Growth

#### 4.5 Europe Antihyperuricemic Agents Sales Growth

#### 4.6 Middle East & Africa Antihyperuricemic Agents Sales Growth



## **5 AMERICAS**

### 5.1 Americas Antihyperuricemic Agents Sales by Country

5.1.1 Americas Antihyperuricemic Agents Sales by Country (2018-2023)

5.1.2 Americas Antihyperuricemic Agents Revenue by Country (2018-2023)

### 5.2 Americas Antihyperuricemic Agents Sales by Type

### 5.3 Americas Antihyperuricemic Agents Sales by Application

### 5.4 United States

### 5.5 Canada

### 5.6 Mexico

### 5.7 Brazil

## **6 APAC**

### 6.1 APAC Antihyperuricemic Agents Sales by Region

6.1.1 APAC Antihyperuricemic Agents Sales by Region (2018-2023)

6.1.2 APAC Antihyperuricemic Agents Revenue by Region (2018-2023)

### 6.2 APAC Antihyperuricemic Agents Sales by Type

### 6.3 APAC Antihyperuricemic Agents Sales by Application

### 6.4 China

### 6.5 Japan

### 6.6 South Korea

### 6.7 Southeast Asia

### 6.8 India

### 6.9 Australia

### 6.10 China Taiwan

## **7 EUROPE**

### 7.1 Europe Antihyperuricemic Agents by Country

7.1.1 Europe Antihyperuricemic Agents Sales by Country (2018-2023)

7.1.2 Europe Antihyperuricemic Agents Revenue by Country (2018-2023)

### 7.2 Europe Antihyperuricemic Agents Sales by Type

### 7.3 Europe Antihyperuricemic Agents Sales by Application

### 7.4 Germany

### 7.5 France

### 7.6 UK

### 7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa Antihyperuricemic Agents by Country

8.1.1 Middle East & Africa Antihyperuricemic Agents Sales by Country (2018-2023)

8.1.2 Middle East & Africa Antihyperuricemic Agents Revenue by Country (2018-2023)

8.2 Middle East & Africa Antihyperuricemic Agents Sales by Type

8.3 Middle East & Africa Antihyperuricemic Agents Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Antihyperuricemic Agents

10.3 Manufacturing Process Analysis of Antihyperuricemic Agents

10.4 Industry Chain Structure of Antihyperuricemic Agents

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Antihyperuricemic Agents Distributors

11.3 Antihyperuricemic Agents Customer

## **12 WORLD FORECAST REVIEW FOR ANTIHYPERURICEMIC AGENTS BY GEOGRAPHIC REGION**

- 12.1 Global Antihyperuricemic Agents Market Size Forecast by Region
  - 12.1.1 Global Antihyperuricemic Agents Forecast by Region (2024-2029)
  - 12.1.2 Global Antihyperuricemic Agents Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Antihyperuricemic Agents Forecast by Type
- 12.7 Global Antihyperuricemic Agents Forecast by Application

## **13 KEY PLAYERS ANALYSIS**

- 13.1 Takeda Pharmaceuticals
  - 13.1.1 Takeda Pharmaceuticals Company Information
  - 13.1.2 Takeda Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.1.3 Takeda Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.1.4 Takeda Pharmaceuticals Main Business Overview
  - 13.1.5 Takeda Pharmaceuticals Latest Developments
- 13.2 Hikma
  - 13.2.1 Hikma Company Information
  - 13.2.2 Hikma Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.2.3 Hikma Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.2.4 Hikma Main Business Overview
  - 13.2.5 Hikma Latest Developments
- 13.3 Wockhardt
  - 13.3.1 Wockhardt Company Information
  - 13.3.2 Wockhardt Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.3.3 Wockhardt Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.3.4 Wockhardt Main Business Overview
  - 13.3.5 Wockhardt Latest Developments
- 13.4 West Ward Pharmaceuticals
  - 13.4.1 West Ward Pharmaceuticals Company Information
  - 13.4.2 West Ward Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications

13.4.3 West Ward Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 West Ward Pharmaceuticals Main Business Overview

13.4.5 West Ward Pharmaceuticals Latest Developments

13.5 Rhea Pharmaceutical

13.5.1 Rhea Pharmaceutical Company Information

13.5.2 Rhea Pharmaceutical Antihyperuricemic Agents Product Portfolios and Specifications

13.5.3 Rhea Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Rhea Pharmaceutical Main Business Overview

13.5.5 Rhea Pharmaceutical Latest Developments

13.6 Medinova

13.6.1 Medinova Company Information

13.6.2 Medinova Antihyperuricemic Agents Product Portfolios and Specifications

13.6.3 Medinova Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Medinova Main Business Overview

13.6.5 Medinova Latest Developments

13.7 Odan Laboratories

13.7.1 Odan Laboratories Company Information

13.7.2 Odan Laboratories Antihyperuricemic Agents Product Portfolios and Specifications

13.7.3 Odan Laboratories Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Odan Laboratories Main Business Overview

13.7.5 Odan Laboratories Latest Developments

13.8 TEIJIN

13.8.1 TEIJIN Company Information

13.8.2 TEIJIN Antihyperuricemic Agents Product Portfolios and Specifications

13.8.3 TEIJIN Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 TEIJIN Main Business Overview

13.8.5 TEIJIN Latest Developments

13.9 Casper Pharma

13.9.1 Casper Pharma Company Information

13.9.2 Casper Pharma Antihyperuricemic Agents Product Portfolios and Specifications

13.9.3 Casper Pharma Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.9.4 Casper Pharma Main Business Overview
- 13.9.5 Casper Pharma Latest Developments
- 13.10 Dr. Reddys Laboratories
  - 13.10.1 Dr. Reddys Laboratories Company Information
  - 13.10.2 Dr. Reddys Laboratories Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.10.3 Dr. Reddys Laboratories Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.10.4 Dr. Reddys Laboratories Main Business Overview
  - 13.10.5 Dr. Reddys Laboratories Latest Developments
- 13.11 Teva
  - 13.11.1 Teva Company Information
  - 13.11.2 Teva Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.11.3 Teva Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.11.4 Teva Main Business Overview
  - 13.11.5 Teva Latest Developments
- 13.12 Zydus Pharmaceuticals
  - 13.12.1 Zydus Pharmaceuticals Company Information
  - 13.12.2 Zydus Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.12.3 Zydus Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.12.4 Zydus Pharmaceuticals Main Business Overview
  - 13.12.5 Zydus Pharmaceuticals Latest Developments
- 13.13 Mylan
  - 13.13.1 Mylan Company Information
  - 13.13.2 Mylan Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.13.3 Mylan Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.13.4 Mylan Main Business Overview
  - 13.13.5 Mylan Latest Developments
- 13.14 Sun Pharmaceutical
  - 13.14.1 Sun Pharmaceutical Company Information
  - 13.14.2 Sun Pharmaceutical Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.14.3 Sun Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.14.4 Sun Pharmaceutical Main Business Overview

- 13.14.5 Sun Pharmaceutical Latest Developments
- 13.15 APOTEX
  - 13.15.1 APOTEX Company Information
  - 13.15.2 APOTEX Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.15.3 APOTEX Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.15.4 APOTEX Main Business Overview
  - 13.15.5 APOTEX Latest Developments
- 13.16 NorthStar Healthcare
  - 13.16.1 NorthStar Healthcare Company Information
  - 13.16.2 NorthStar Healthcare Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.16.3 NorthStar Healthcare Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.16.4 NorthStar Healthcare Main Business Overview
  - 13.16.5 NorthStar Healthcare Latest Developments
- 13.17 Ipca Laboratories
  - 13.17.1 Ipca Laboratories Company Information
  - 13.17.2 Ipca Laboratories Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.17.3 Ipca Laboratories Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.17.4 Ipca Laboratories Main Business Overview
  - 13.17.5 Ipca Laboratories Latest Developments
- 13.18 Accord Healthcare
  - 13.18.1 Accord Healthcare Company Information
  - 13.18.2 Accord Healthcare Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.18.3 Accord Healthcare Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.18.4 Accord Healthcare Main Business Overview
  - 13.18.5 Accord Healthcare Latest Developments
- 13.19 Gentec Pharmaceutical Group
  - 13.19.1 Gentec Pharmaceutical Group Company Information
  - 13.19.2 Gentec Pharmaceutical Group Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.19.3 Gentec Pharmaceutical Group Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.19.4 Gentec Pharmaceutical Group Main Business Overview

- 13.19.5 Gentec Pharmaceutical Group Latest Developments
- 13.20 Indoco Remedies
  - 13.20.1 Indoco Remedies Company Information
  - 13.20.2 Indoco Remedies Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.20.3 Indoco Remedies Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.20.4 Indoco Remedies Main Business Overview
  - 13.20.5 Indoco Remedies Latest Developments
- 13.21 Lupin
  - 13.21.1 Lupin Company Information
  - 13.21.2 Lupin Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.21.3 Lupin Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.21.4 Lupin Main Business Overview
  - 13.21.5 Lupin Latest Developments
- 13.22 Waterstone Pharmaceuticals
  - 13.22.1 Waterstone Pharmaceuticals Company Information
  - 13.22.2 Waterstone Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.22.3 Waterstone Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.22.4 Waterstone Pharmaceuticals Main Business Overview
  - 13.22.5 Waterstone Pharmaceuticals Latest Developments
- 13.23 ALP Pharm
  - 13.23.1 ALP Pharm Company Information
  - 13.23.2 ALP Pharm Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.23.3 ALP Pharm Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.23.4 ALP Pharm Main Business Overview
  - 13.23.5 ALP Pharm Latest Developments
- 13.24 Jiangsu Hengrui Medicine
  - 13.24.1 Jiangsu Hengrui Medicine Company Information
  - 13.24.2 Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Portfolios and Specifications
  - 13.24.3 Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.24.4 Jiangsu Hengrui Medicine Main Business Overview
  - 13.24.5 Jiangsu Hengrui Medicine Latest Developments

### 13.25 Jiangsu Wanbang Biopharmaceuticals

13.25.1 Jiangsu Wanbang Biopharmaceuticals Company Information

13.25.2 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications

13.25.3 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.25.4 Jiangsu Wanbang Biopharmaceuticals Main Business Overview

13.25.5 Jiangsu Wanbang Biopharmaceuticals Latest Developments

### 13.26 Hangzhou Zhuyangxin Pharmaceutical

13.26.1 Hangzhou Zhuyangxin Pharmaceutical Company Information

13.26.2 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Portfolios and Specifications

13.26.3 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.26.4 Hangzhou Zhuyangxin Pharmaceutical Main Business Overview

13.26.5 Hangzhou Zhuyangxin Pharmaceutical Latest Developments

### 13.27 YiChang HEC ChangJiang Pharmaceutical

13.27.1 YiChang HEC ChangJiang Pharmaceutical Company Information

13.27.2 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Portfolios and Specifications

13.27.3 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.27.4 YiChang HEC ChangJiang Pharmaceutical Main Business Overview

13.27.5 YiChang HEC ChangJiang Pharmaceutical Latest Developments

### 13.28 KPC Pharmaceuticals

13.28.1 KPC Pharmaceuticals Company Information

13.28.2 KPC Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications

13.28.3 KPC Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.28.4 KPC Pharmaceuticals Main Business Overview

13.28.5 KPC Pharmaceuticals Latest Developments

### 13.29 Tonghua Limin

13.29.1 Tonghua Limin Company Information

13.29.2 Tonghua Limin Antihyperuricemic Agents Product Portfolios and Specifications

13.29.3 Tonghua Limin Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.29.4 Tonghua Limin Main Business Overview

13.29.5 Tonghua Limin Latest Developments



### 13.30 Beijing Jialin Pharmaceutical

13.30.1 Beijing Jialin Pharmaceutical Company Information

13.30.2 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Portfolios and Specifications

13.30.3 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2018-2023)

13.30.4 Beijing Jialin Pharmaceutical Main Business Overview

13.30.5 Beijing Jialin Pharmaceutical Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Antihyperuricemic Agents Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Antihyperuricemic Agents Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Inhibit Uric Acid Production Agents

Table 4. Major Players of Promote Uric Acid Excretion Agents

Table 5. Major Players of Others

Table 6. Global Antihyperuricemic Agents Sales by Type (2018-2023) & (K Units)

Table 7. Global Antihyperuricemic Agents Sales Market Share by Type (2018-2023)

Table 8. Global Antihyperuricemic Agents Revenue by Type (2018-2023) & (\$ million)

Table 9. Global Antihyperuricemic Agents Revenue Market Share by Type (2018-2023)

Table 10. Global Antihyperuricemic Agents Sale Price by Type (2018-2023) & (US\$/Unit)

Table 11. Global Antihyperuricemic Agents Sales by Application (2018-2023) & (K Units)

Table 12. Global Antihyperuricemic Agents Sales Market Share by Application (2018-2023)

Table 13. Global Antihyperuricemic Agents Revenue by Application (2018-2023)

Table 14. Global Antihyperuricemic Agents Revenue Market Share by Application (2018-2023)

Table 15. Global Antihyperuricemic Agents Sale Price by Application (2018-2023) & (US\$/Unit)

Table 16. Global Antihyperuricemic Agents Sales by Company (2018-2023) & (K Units)

Table 17. Global Antihyperuricemic Agents Sales Market Share by Company (2018-2023)

Table 18. Global Antihyperuricemic Agents Revenue by Company (2018-2023) (\$ Millions)

Table 19. Global Antihyperuricemic Agents Revenue Market Share by Company (2018-2023)

Table 20. Global Antihyperuricemic Agents Sale Price by Company (2018-2023) & (US\$/Unit)

Table 21. Key Manufacturers Antihyperuricemic Agents Producing Area Distribution and Sales Area

Table 22. Players Antihyperuricemic Agents Products Offered

Table 23. Antihyperuricemic Agents Concentration Ratio (CR3, CR5 and CR10) &

(2018-2023)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Antihyperuricemic Agents Sales by Geographic Region (2018-2023) & (K Units)

Table 27. Global Antihyperuricemic Agents Sales Market Share Geographic Region (2018-2023)

Table 28. Global Antihyperuricemic Agents Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 29. Global Antihyperuricemic Agents Revenue Market Share by Geographic Region (2018-2023)

Table 30. Global Antihyperuricemic Agents Sales by Country/Region (2018-2023) & (K Units)

Table 31. Global Antihyperuricemic Agents Sales Market Share by Country/Region (2018-2023)

Table 32. Global Antihyperuricemic Agents Revenue by Country/Region (2018-2023) & (\$ millions)

Table 33. Global Antihyperuricemic Agents Revenue Market Share by Country/Region (2018-2023)

Table 34. Americas Antihyperuricemic Agents Sales by Country (2018-2023) & (K Units)

Table 35. Americas Antihyperuricemic Agents Sales Market Share by Country (2018-2023)

Table 36. Americas Antihyperuricemic Agents Revenue by Country (2018-2023) & (\$ Millions)

Table 37. Americas Antihyperuricemic Agents Revenue Market Share by Country (2018-2023)

Table 38. Americas Antihyperuricemic Agents Sales by Type (2018-2023) & (K Units)

Table 39. Americas Antihyperuricemic Agents Sales by Application (2018-2023) & (K Units)

Table 40. APAC Antihyperuricemic Agents Sales by Region (2018-2023) & (K Units)

Table 41. APAC Antihyperuricemic Agents Sales Market Share by Region (2018-2023)

Table 42. APAC Antihyperuricemic Agents Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Antihyperuricemic Agents Revenue Market Share by Region (2018-2023)

Table 44. APAC Antihyperuricemic Agents Sales by Type (2018-2023) & (K Units)

Table 45. APAC Antihyperuricemic Agents Sales by Application (2018-2023) & (K Units)

Table 46. Europe Antihyperuricemic Agents Sales by Country (2018-2023) & (K Units)

Table 47. Europe Antihyperuricemic Agents Sales Market Share by Country

(2018-2023)

Table 48. Europe Antihyperuricemic Agents Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Antihyperuricemic Agents Revenue Market Share by Country (2018-2023)

Table 50. Europe Antihyperuricemic Agents Sales by Type (2018-2023) & (K Units)

Table 51. Europe Antihyperuricemic Agents Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa Antihyperuricemic Agents Sales by Country (2018-2023) & (K Units)

Table 53. Middle East & Africa Antihyperuricemic Agents Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Antihyperuricemic Agents Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Antihyperuricemic Agents Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Antihyperuricemic Agents Sales by Type (2018-2023) & (K Units)

Table 57. Middle East & Africa Antihyperuricemic Agents Sales by Application (2018-2023) & (K Units)

Table 58. Key Market Drivers & Growth Opportunities of Antihyperuricemic Agents

Table 59. Key Market Challenges & Risks of Antihyperuricemic Agents

Table 60. Key Industry Trends of Antihyperuricemic Agents

Table 61. Antihyperuricemic Agents Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. Antihyperuricemic Agents Distributors List

Table 64. Antihyperuricemic Agents Customer List

Table 65. Global Antihyperuricemic Agents Sales Forecast by Region (2024-2029) & (K Units)

Table 66. Global Antihyperuricemic Agents Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 67. Americas Antihyperuricemic Agents Sales Forecast by Country (2024-2029) & (K Units)

Table 68. Americas Antihyperuricemic Agents Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 69. APAC Antihyperuricemic Agents Sales Forecast by Region (2024-2029) & (K Units)

Table 70. APAC Antihyperuricemic Agents Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 71. Europe Antihyperuricemic Agents Sales Forecast by Country (2024-2029) & (K Units)

Table 72. Europe Antihyperuricemic Agents Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 73. Middle East & Africa Antihyperuricemic Agents Sales Forecast by Country (2024-2029) & (K Units)

Table 74. Middle East & Africa Antihyperuricemic Agents Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 75. Global Antihyperuricemic Agents Sales Forecast by Type (2024-2029) & (K Units)

Table 76. Global Antihyperuricemic Agents Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 77. Global Antihyperuricemic Agents Sales Forecast by Application (2024-2029) & (K Units)

Table 78. Global Antihyperuricemic Agents Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 79. Takeda Pharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 80. Takeda Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications

Table 81. Takeda Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 82. Takeda Pharmaceuticals Main Business

Table 83. Takeda Pharmaceuticals Latest Developments

Table 84. Hikma Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 85. Hikma Antihyperuricemic Agents Product Portfolios and Specifications

Table 86. Hikma Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. Hikma Main Business

Table 88. Hikma Latest Developments

Table 89. Wockhardt Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 90. Wockhardt Antihyperuricemic Agents Product Portfolios and Specifications

Table 91. Wockhardt Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Wockhardt Main Business

Table 93. Wockhardt Latest Developments

Table 94. West Ward Pharmaceuticals Basic Information, Antihyperuricemic Agents

Manufacturing Base, Sales Area and Its Competitors

Table 95. West Ward Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications

Table 96. West Ward Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. West Ward Pharmaceuticals Main Business

Table 98. West Ward Pharmaceuticals Latest Developments

Table 99. Rhea Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 100. Rhea Pharmaceutical Antihyperuricemic Agents Product Portfolios and Specifications

Table 101. Rhea Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Rhea Pharmaceutical Main Business

Table 103. Rhea Pharmaceutical Latest Developments

Table 104. Medinova Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 105. Medinova Antihyperuricemic Agents Product Portfolios and Specifications

Table 106. Medinova Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 107. Medinova Main Business

Table 108. Medinova Latest Developments

Table 109. Odan Laboratories Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 110. Odan Laboratories Antihyperuricemic Agents Product Portfolios and Specifications

Table 111. Odan Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 112. Odan Laboratories Main Business

Table 113. Odan Laboratories Latest Developments

Table 114. TEIJIN Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 115. TEIJIN Antihyperuricemic Agents Product Portfolios and Specifications

Table 116. TEIJIN Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 117. TEIJIN Main Business

Table 118. TEIJIN Latest Developments

Table 119. Casper Pharma Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

- Table 120. Casper Pharma Antihyperuricemic Agents Product Portfolios and Specifications
- Table 121. Casper Pharma Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 122. Casper Pharma Main Business
- Table 123. Casper Pharma Latest Developments
- Table 124. Dr. Reddys Laboratories Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors
- Table 125. Dr. Reddys Laboratories Antihyperuricemic Agents Product Portfolios and Specifications
- Table 126. Dr. Reddys Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 127. Dr. Reddys Laboratories Main Business
- Table 128. Dr. Reddys Laboratories Latest Developments
- Table 129. Teva Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors
- Table 130. Teva Antihyperuricemic Agents Product Portfolios and Specifications
- Table 131. Teva Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 132. Teva Main Business
- Table 133. Teva Latest Developments
- Table 134. Zydus Pharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors
- Table 135. Zydus Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications
- Table 136. Zydus Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 137. Zydus Pharmaceuticals Main Business
- Table 138. Zydus Pharmaceuticals Latest Developments
- Table 139. Mylan Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors
- Table 140. Mylan Antihyperuricemic Agents Product Portfolios and Specifications
- Table 141. Mylan Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 142. Mylan Main Business
- Table 143. Mylan Latest Developments
- Table 144. Sun Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors
- Table 145. Sun Pharmaceutical Antihyperuricemic Agents Product Portfolios and

## Specifications

Table 146. Sun Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 147. Sun Pharmaceutical Main Business

Table 148. Sun Pharmaceutical Latest Developments

Table 149. APOTEX Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 150. APOTEX Antihyperuricemic Agents Product Portfolios and Specifications

Table 151. APOTEX Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 152. APOTEX Main Business

Table 153. APOTEX Latest Developments

Table 154. NorthStar Healthcare Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 155. NorthStar Healthcare Antihyperuricemic Agents Product Portfolios and Specifications

Table 156. NorthStar Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 157. NorthStar Healthcare Main Business

Table 158. NorthStar Healthcare Latest Developments

Table 159. Ipca Laboratories Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 160. Ipca Laboratories Antihyperuricemic Agents Product Portfolios and Specifications

Table 161. Ipca Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 162. Ipca Laboratories Main Business

Table 163. Ipca Laboratories Latest Developments

Table 164. Accord Healthcare Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 165. Accord Healthcare Antihyperuricemic Agents Product Portfolios and Specifications

Table 166. Accord Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 167. Accord Healthcare Main Business

Table 168. Accord Healthcare Latest Developments

Table 169. Gentec Pharmaceutical Group Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 170. Gentec Pharmaceutical Group Antihyperuricemic Agents Product Portfolios



and Specifications

Table 171. Gentec Pharmaceutical Group Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 172. Gentec Pharmaceutical Group Main Business

Table 173. Gentec Pharmaceutical Group Latest Developments

Table 174. Indoco Remedies Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 175. Indoco Remedies Antihyperuricemic Agents Product Portfolios and Specifications

Table 176. Indoco Remedies Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 177. Indoco Remedies Main Business

Table 178. Indoco Remedies Latest Developments

Table 179. Lupin Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 180. Lupin Antihyperuricemic Agents Product Portfolios and Specifications

Table 181. Lupin Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 182. Lupin Main Business

Table 183. Lupin Latest Developments

Table 184. Waterstone Pharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 185. Waterstone Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications

Table 186. Waterstone Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 187. Waterstone Pharmaceuticals Main Business

Table 188. Waterstone Pharmaceuticals Latest Developments

Table 189. ALP Pharm Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 190. ALP Pharm Antihyperuricemic Agents Product Portfolios and Specifications

Table 191. ALP Pharm Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 192. ALP Pharm Main Business

Table 193. ALP Pharm Latest Developments

Table 194. Jiangsu Hengrui Medicine Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 195. Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Portfolios and Specifications

Table 196. Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 197. Jiangsu Hengrui Medicine Main Business

Table 198. Jiangsu Hengrui Medicine Latest Developments

Table 199. Jiangsu Wanbang Biopharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 200. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications

Table 201. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 202. Jiangsu Wanbang Biopharmaceuticals Main Business

Table 203. Jiangsu Wanbang Biopharmaceuticals Latest Developments

Table 204. Hangzhou Zhuyangxin Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 205. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Portfolios and Specifications

Table 206. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 207. Hangzhou Zhuyangxin Pharmaceutical Main Business

Table 208. Hangzhou Zhuyangxin Pharmaceutical Latest Developments

Table 209. YiChang HEC ChangJiang Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 210. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Portfolios and Specifications

Table 211. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 212. YiChang HEC ChangJiang Pharmaceutical Main Business

Table 213. YiChang HEC ChangJiang Pharmaceutical Latest Developments

Table 214. KPC Pharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 215. KPC Pharmaceuticals Antihyperuricemic Agents Product Portfolios and Specifications

Table 216. KPC Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 217. KPC Pharmaceuticals Main Business

Table 218. KPC Pharmaceuticals Latest Developments

Table 219. Tonghua Limin Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 220. Tonghua Limin Antihyperuricemic Agents Product Portfolios and

## Specifications

Table 221. Tonghua Limin Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 222. Tonghua Limin Main Business

Table 223. Tonghua Limin Latest Developments

Table 224. Beijing Jialin Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 225. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Portfolios and Specifications

Table 226. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 227. Beijing Jialin Pharmaceutical Main Business

Table 228. Beijing Jialin Pharmaceutical Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Antihyperuricemic Agents
- Figure 2. Antihyperuricemic Agents Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Antihyperuricemic Agents Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Antihyperuricemic Agents Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Antihyperuricemic Agents Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Inhibit Uric Acid Production Agents
- Figure 10. Product Picture of Promote Uric Acid Excretion Agents
- Figure 11. Product Picture of Others
- Figure 12. Global Antihyperuricemic Agents Sales Market Share by Type in 2022
- Figure 13. Global Antihyperuricemic Agents Revenue Market Share by Type (2018-2023)
- Figure 14. Antihyperuricemic Agents Consumed in Hospital Pharmacies
- Figure 15. Global Antihyperuricemic Agents Market: Hospital Pharmacies (2018-2023) & (K Units)
- Figure 16. Antihyperuricemic Agents Consumed in Retail Pharmacies
- Figure 17. Global Antihyperuricemic Agents Market: Retail Pharmacies (2018-2023) & (K Units)
- Figure 18. Antihyperuricemic Agents Consumed in Online Pharmacies
- Figure 19. Global Antihyperuricemic Agents Market: Online Pharmacies (2018-2023) & (K Units)
- Figure 20. Global Antihyperuricemic Agents Sales Market Share by Application (2022)
- Figure 21. Global Antihyperuricemic Agents Revenue Market Share by Application in 2022
- Figure 22. Antihyperuricemic Agents Sales Market by Company in 2022 (K Units)
- Figure 23. Global Antihyperuricemic Agents Sales Market Share by Company in 2022
- Figure 24. Antihyperuricemic Agents Revenue Market by Company in 2022 (\$ Million)
- Figure 25. Global Antihyperuricemic Agents Revenue Market Share by Company in 2022
- Figure 26. Global Antihyperuricemic Agents Sales Market Share by Geographic Region (2018-2023)
- Figure 27. Global Antihyperuricemic Agents Revenue Market Share by Geographic

## Region in 2022

Figure 28. Americas Antihyperuricemic Agents Sales 2018-2023 (K Units)

Figure 29. Americas Antihyperuricemic Agents Revenue 2018-2023 (\$ Millions)

Figure 30. APAC Antihyperuricemic Agents Sales 2018-2023 (K Units)

Figure 31. APAC Antihyperuricemic Agents Revenue 2018-2023 (\$ Millions)

Figure 32. Europe Antihyperuricemic Agents Sales 2018-2023 (K Units)

Figure 33. Europe Antihyperuricemic Agents Revenue 2018-2023 (\$ Millions)

Figure 34. Middle East & Africa Antihyperuricemic Agents Sales 2018-2023 (K Units)

Figure 35. Middle East & Africa Antihyperuricemic Agents Revenue 2018-2023 (\$ Millions)

Figure 36. Americas Antihyperuricemic Agents Sales Market Share by Country in 2022

Figure 37. Americas Antihyperuricemic Agents Revenue Market Share by Country in 2022

Figure 38. Americas Antihyperuricemic Agents Sales Market Share by Type (2018-2023)

Figure 39. Americas Antihyperuricemic Agents Sales Market Share by Application (2018-2023)

Figure 40. United States Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Canada Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Mexico Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Brazil Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 44. APAC Antihyperuricemic Agents Sales Market Share by Region in 2022

Figure 45. APAC Antihyperuricemic Agents Revenue Market Share by Regions in 2022

Figure 46. APAC Antihyperuricemic Agents Sales Market Share by Type (2018-2023)

Figure 47. APAC Antihyperuricemic Agents Sales Market Share by Application (2018-2023)

Figure 48. China Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Japan Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 50. South Korea Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Southeast Asia Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 52. India Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Australia Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 54. China Taiwan Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Europe Antihyperuricemic Agents Sales Market Share by Country in 2022

Figure 56. Europe Antihyperuricemic Agents Revenue Market Share by Country in 2022

- Figure 57. Europe Antihyperuricemic Agents Sales Market Share by Type (2018-2023)
- Figure 58. Europe Antihyperuricemic Agents Sales Market Share by Application (2018-2023)
- Figure 59. Germany Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 60. France Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 61. UK Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 62. Italy Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 63. Russia Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 64. Middle East & Africa Antihyperuricemic Agents Sales Market Share by Country in 2022
- Figure 65. Middle East & Africa Antihyperuricemic Agents Revenue Market Share by Country in 2022
- Figure 66. Middle East & Africa Antihyperuricemic Agents Sales Market Share by Type (2018-2023)
- Figure 67. Middle East & Africa Antihyperuricemic Agents Sales Market Share by Application (2018-2023)
- Figure 68. Egypt Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 69. South Africa Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 70. Israel Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 71. Turkey Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 72. GCC Country Antihyperuricemic Agents Revenue Growth 2018-2023 (\$ Millions)
- Figure 73. Manufacturing Cost Structure Analysis of Antihyperuricemic Agents in 2022
- Figure 74. Manufacturing Process Analysis of Antihyperuricemic Agents
- Figure 75. Industry Chain Structure of Antihyperuricemic Agents
- Figure 76. Channels of Distribution
- Figure 77. Global Antihyperuricemic Agents Sales Market Forecast by Region (2024-2029)
- Figure 78. Global Antihyperuricemic Agents Revenue Market Share Forecast by Region (2024-2029)
- Figure 79. Global Antihyperuricemic Agents Sales Market Share Forecast by Type (2024-2029)
- Figure 80. Global Antihyperuricemic Agents Revenue Market Share Forecast by Type (2024-2029)
- Figure 81. Global Antihyperuricemic Agents Sales Market Share Forecast by Application (2024-2029)
- Figure 82. Global Antihyperuricemic Agents Revenue Market Share Forecast by Application (2024-2029)

## I would like to order

Product name: Global Antihyperuricemic Agents Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G88EC8BD1605EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G88EC8BD1605EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970